We can’t show the full text here under this license. Use the link below to read it at the source.
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
Short-Term Cost per Patient Reaching Treatment Goals with Oral Semaglutide in the United States
AI simplified
Abstract
Oral semaglutide was associated with a cost advantage of USD 15,036 compared to empagliflozin for achieving HbA1c ≤ 6.5%.
- Oral semaglutide resulted in lower treatment costs across all evaluated endpoints for type 2 diabetes.
- For achieving HbA1c < 7.0%, oral semaglutide's cost of control was lower than empagliflozin, sitagliptin, and liraglutide by USD 14,697, 6996, and 346, respectively.
- The double composite endpoint showed oral semaglutide had a lower cost of control by USD 525, 32,277, and 13,011 compared to the other three treatments.
- For the triple composite endpoint, oral semaglutide's cost of control was lower by USD 1255, 7510, and 5774 compared to empagliflozin, sitagliptin, and liraglutide.
AI simplified
Key numbers
15,036 USD
Cost Difference for HbA1c ≤ 6.5%
Cost difference vs. empagliflozin for achieving target HbA1c.
14,697 USD
Cost Difference for HbA1c < 7.0%
Cost difference vs. sitagliptin for achieving target HbA1c.
1,255 USD
Cost Difference for HbA1c < 7.0% without hypoglycemia
Cost difference for composite endpoint vs. empagliflozin.